Drug Combination Therapy
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Conditions
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Trial Timeline
Jan 1, 2026 → Dec 31, 2029
NCT ID
NCT07354984About Drug Combination Therapy
Drug Combination Therapy is a phase 2 stage product being developed by Sun Pharmaceutical for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07354984. Target conditions include Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07354984 | Phase 2 | Recruiting |
Competing Products
4 competing products in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MEDI4736 + Tremelimumab + MEDI4736 + Tremelimumab | AstraZeneca | Phase 2 | 52 |
| pepinemab + pembrolizumab | Merck | Phase 1/2 | 41 |
| Pembrolizumab + Cisplatin + Carboplatin + Gemcitabine | Merck | Phase 2 | 52 |
| Nivolumab + Paclitaxel + Cetuximab + Paclitaxel | Bristol Myers Squibb | Phase 2 | 51 |
Other Products from Sun Pharmaceutical
Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85